<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085419</url>
  </required_header>
  <id_info>
    <org_study_id>11111</org_study_id>
    <nct_id>NCT04085419</nct_id>
  </id_info>
  <brief_title>Osteoporosis in Primary Hyperparathyroidism</brief_title>
  <official_title>Management of Osteoporosis in Patients With Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will prospectively include 40 postmenopausal women with secondary osteoporosis
      due to primary hyperparathyroidism who have refused surgery. Participants will be randomized
      in two groups and treated either with zoledronic acid 5 mg iv once a year or with denosumab
      60 mg sc every 6 months. Investigators will compare the effect of both drugs on bone turnover
      markers and basic laboratory parameters after 3, 12 and 24 months of treatment, and on the
      bone mineral density after 12 and 24 months of treatment. All participants will take
      cholecalciferol 800 - 1000 IU daily.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density after one year of treatment</measure>
    <time_frame>one year</time_frame>
    <description>Dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTX after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Unit of Measure: pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrected calcium after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Unit of Measure: mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone mineral density after two years of treatment</measure>
    <time_frame>two years</time_frame>
    <description>Dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTX after 12 months of treatment</measure>
    <time_frame>one year</time_frame>
    <description>Unit of Measure: pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTX after 24 months of treatment</measure>
    <time_frame>two years</time_frame>
    <description>Unit of Measure: pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PINP after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Unit of Measure: µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PINP after 12 months of treatment</measure>
    <time_frame>one year</time_frame>
    <description>Unit of Measure: µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PINP after 24 months of treatment</measure>
    <time_frame>two years</time_frame>
    <description>Unit of Measure: µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone-specific alkaline phosphatase (BAP) after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Unit of Measure: µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone-specific alkaline phosphatase (BAP) after 12 months of treatment</measure>
    <time_frame>one year</time_frame>
    <description>Unit of Measure: µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone-specific alkaline phosphatase (BAP) after 24 months of treatment</measure>
    <time_frame>two years</time_frame>
    <description>Unit of Measure: µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrected calcium after 12 months of treatment</measure>
    <time_frame>one year</time_frame>
    <description>Unit of Measure: mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrected calcium after 24 months of treatment</measure>
    <time_frame>two years</time_frame>
    <description>Unit of Measure: mmol/L</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>denosumab 60 mg subcutaneously every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zoledronic acid 5 mg intravenously once a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab 60 MG/ML Prefilled Syringe [Prolia]</intervention_name>
    <description>denosumab 60 mg subcutaneously every 6 months</description>
    <arm_group_label>denosumab</arm_group_label>
    <other_name>Xgeva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>zoledronic acid 5 mg intravenously once a year</description>
    <arm_group_label>zoledronic acid</arm_group_label>
    <other_name>Aclasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (&gt;12 months after last menstrual period) with primary
             hyperparathyroidism and with osteoporosis on Dual Energy Xray Absorptiometry (DXA)
             (according to International Society for Clinical Densitometry (ISCD) - criteria)
             and/or osteoporotic fracture of the vertebra or hip

        Exclusion Criteria:

          -  The patient is not able to give informed consent

          -  other classic complications of primary hyperparathyroidism (e.g. kidney stones, renal
             insufficiency)

          -  serum albumin-corrected calcium level &gt; 2.85 mmol/L (except when the patient is
             reluctant to undergo surgical treatment)

          -  osteoporosis treatment less than a year ago, less than two years ago in the case of
             oral bisphosphonate, less than three years ago in the case of parenteral
             bisphosphonate

          -  bilateral hip endoprosthesis

          -  additional causes for secondary osteoporosis (other than vitamin D deficiency) and
             pathological laboratory findings that are incompatible with the Summary of Product
             Characteristics (SmPC) of both medicines

          -  cancer, except if in stable remission of more than 5 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomaz Kocjan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Mlekus Kozamernik, MD</last_name>
    <phone>+38631765865</phone>
    <email>katarina.mlekuskozamernik@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeta Stepanovic, RN</last_name>
    <phone>+38615224864</phone>
    <email>elizabeta.stepanovic@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endocrinology Department</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeta Stepanovic, RN</last_name>
      <phone>+38615224864</phone>
      <email>elizabeta.stepanovic@kclj.si</email>
    </contact>
    <investigator>
      <last_name>Mojca Jensterle Sever, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonela Sabati Rajic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Groti Resman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matej Rakusa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Bozic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Krokter Kogoj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarina Mlekus Kozamernik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 7, 2019</last_update_submitted>
  <last_update_submitted_qc>September 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Tomaz Kocjan</investigator_full_name>
    <investigator_title>Professor Tomaz Kocjan, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>zoledronic acid</keyword>
  <keyword>denosumab</keyword>
  <keyword>primary hyperparathyroidism</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Bone mineral density, bone turnover markers and basic laboratory results will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will become available in 3 years. They will be available for 5 years.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

